Experimental drug DFMO offered to kids with rare cancers
NCT ID NCT03581240
First seen Feb 22, 2026 · Last updated May 01, 2026 · Updated 7 times
Summary
This program provides the drug DFMO to children and young adults (up to age 30) with rare, relapsed tumors like neuroblastoma or medulloblastoma that have certain genetic markers. The goal is to control the disease by targeting these markers. Participants must have tried other treatments first.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn State Milton S. Hershey Medical Center and Children's Hospital
AVAILABLEHershey, Pennsylvania, 17033, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.